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& Neil Vargesson1,#
Angiogenesis, the formation of new blood vessels, is essential for tumor growth, stabilization and 
progression. Angiogenesis inhibitors are now widely used in the clinic; however, there are relatively 
few published studies on the mechanism of their presumed teratogenic effects. To address this issue, 
we screened a variety of angiogenesis inhibitors in developing zebrafish and chicken embryo models 
to assess for developmental defects and potential teratogenic effects. We confirmed previous reports 
that sunitinib, sorafenib and TNP-470 are teratogenic and demonstrate that axitinib, pazopanib, 
vandetanib, and everolimus are also teratogens in these models. A dose response study identified 
the drugs inhibit HUVEC cell proliferation in vitro, and also target the developing blood vessels of 
embryos in vivo. This provides further evidence for the potential risk of fetal toxicity when using these 
drugs in a clinical setting, and emphasizes the importance of the development and maintenance of 
the vasculature in the embryo. We conclude that angiogenesis inhibitors, regardless of the molecular 
target, are teratogenic when exposed to chicken embryos.
Angiogenesis, the formation of new vessels, is a complex process that has critical importance in physiologic 
(such as embryogenesis) and pathologic conditions. Several studies have shown a correlation between high lev-
els of angiogenic factors and increased tumor aggression1–3. Many current treatments incorporate the use of 
anti-angiogenic drugs to restrict the vascular supply to the tumor, reducing the mortality and morbidity from 
cancers by interfering with signaling mechanisms that promote the growth and survival of new blood vessels4, 
and have shown the potential for clinical benefit in a variety of cancers5–10. Recent years have seen an increase in 
the use of these agents for non-cancer conditions where inappropriate angiogenesis is a factor for disease progres-
sion; including ocular diseases11,12, Crohns disease13,14, as anti-obesity agents4,15 and have also shown promise in 
endometriosis16–18.
Given that the teratogenic drug thalidomide is thought to produce embryonic defects by inhibition of growth 
of naive, newly forming blood vessels, it is possible that anti-angiogenic drugs used during pregnancy could 
induce birth defects in a developing embryo19–23. Because of this possibility, the regulatory approvals state a con-
traindication of use during pregnancy within the packaging and safety information. Few data are available on 
the safety of anti-angiogenic drugs when given during pregnancy including the monoclonal anti-VEGF anti-
body bevacizumab24,25. The only available studies in pregnancy come from the use of intravitreal bevacizumab 
injections in the ophthalmic setting26. Bevacizumab has been well-studied in preclinical models which showed 
teratogenicity in rabbits at twice the recommended intravenous human dose and exhibited embryotoxicity and 
dose-dependent placental transfer during all gestational ages in rats27,28. However, there are very limited pub-
lished reports of other anti-angiogenic targeted agents and their potential teratogenic effects, particularly their 
mechanism of teratogenicity in preclinical models.
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To investigate if anti-angiogenic drugs are teratogenic and to shed light on whether similar or shared mecha-
nisms are used by these drugs to cause teratogenesis, a cohort of targeted agents, currently approved and used to 
treat patients, or in preclinical development, were screened for teratogenicity using the chicken embryo model 
system. In addition, we used the stable transgenic zebrafish line, fli1:EGFP29, where the endothelial cells express 
green fluorescent protein throughout development, allowing blood vessels to be studied live following drug 
exposure. Both chicken and zebrafish embryos have been shown to be sensitive to exposure to toxicants and 
anti-angiogenic compounds during early development20,30–33.
We investigated a variety of angiogenesis inhibitors with different molecular targets including the 
small-molecule tyrosine kinase inhibitors sunitinib, vandetanib, pazopanib, axitinib, and sorafenib, the mam-
malian target of rapamycin (mTOR) inhibitor everolimus, the methionine aminopeptidase 2 (metAP2) inhibitor 
TNP-470 (a fumagillin analog) and CPS49 (a thalidomide analog). Previous studies of TNP-470, sunitinib and 
sorafenib in animal models including mice34,35, rats, zebrafish and rabbits36–39 and regulatory prescribing infor-
mation indicates these drugs are potential teratogens (Table 1). Our study aims to determine if all the drugs 
tested target newly forming vessels to cause defect, and if the defects are comparable, regardless of the differing 
downstream molecular targets.
We found that every drug showed toxicity and teratogenicity to varying degrees in our developmental models, 
and inhibited cell proliferation in human umbilical vein endothelial cells (HUVECs) in vitro. The most potent 
compounds were sunitinib, axitinib, pazopanib and sorafenib, which displayed effects at lower concentrations 
than the other agents. Everolimus, vandetanib and TNP-470 were the least potent in these assays but still induced 
defects. Mechanistically, all of these compounds were shown to target newly forming blood vessels in the devel-
oping embryo, similar to a primary mechanism of thalidomide-induced teratogenesis20,22. We conclude that these 
anti-angiogenic compounds have the potential to be teratogenic, exhibit a common mechanism of teratogenicity, 
which is the loss of correct formation and development of naïve blood vessels, and emphasize that safety in pre-
scribing is crucial for anti-angiogenic drugs, especially in women of childbearing age.
Results
Anti-angiogenic compounds decrease endothelial cell proliferation over a concentration gra-
dient in vitro. In order to confirm the inhibitory effect of the compounds on blood vessel formation and 
to establish an IC50 for the compounds in vitro we applied the compounds to an endothelial cell line, Human 
Umbilical Venous Endothelial Cells (HUVEC) (n = 9). With the exception of vandetanib and pazopanib, all com-
pounds reduced endothelial cell proliferation by 50% at 100 nM or less (Fig. 1). Based on our cell proliferation 
assay axitinib was seen to be the most potent compound (IC50 < 0.5 nM), followed by sunitinib, TNP-470 and 
everolimus (IC50 < 10 nM), and CPS49 and sorafenib (IC50 < 50 nM).
Anti-angiogenic compounds are teratogenic in the developing chicken embryo. We then 
administered the compounds to developing chicken embryos to observe any teratogenic effects. Chicken embryos 
have previously been used in drug screening analyses due to their sensitivity to teratogens and their external 
development allowing easy access to the embryos and rapid monitoring of development20,31–33,40. Each drug was 
tested over a range of concentrations to establish the dose at which they retained a high survival rate (Fig. 2A) 
and such concentrations are relative to, or lower than, human therapeutic doses (Table 1). Previous work in 
our laboratory demonstrated CPS49 has potent anti-angiogenic activity at 10 μg/embryo20. Given the highly 
anti-angiogenic effects of these compounds we initially screened them at the lower concentration of 5 μg/chicken 
embryo. At 48 hours post drug application both the survival rate and the incidence of defects were analyzed. A 
range of concentrations was tested to determine the effects and optimal concentration that was not 100% lethal. 
Embryos treated with just the vehicle 0.1% DMSO showed normal development and high survival rates (85.71%).
In contrast, when treated with sunitinib (5 μg/embryo) the survival rate was reduced to 72%. Of those surviv-
ing, in most embryos limb defects were observed, some also exhibited microopthalmia and spinal cord twisting 
(Fig. 3B). We also observed necrotic or dead areas in the surrounding yolk sac membrane (YSM) (Fig. 3) which 
have also been recorded in other studies of anti-angiogenic drugs20. Similar results were seen with sorafenib appli-
cation (Fig. 3C), at 5 μg/embryo the survival rate decreased to 54.5% and at 10 μg/embryo survival was reduced 
to 47%. Following axitinib application at 5 μg/embryo, no embryos survived the treatment. At 2.5 μg/embryo the 
survival rate increased to 55.5%. Defects were again seen, in particular most embryos exhibited necrosis within 
the surrounding YSM and hemorrhaging (Fig. 3D). Pazopanib treatment at 5 μg/embryo led to a low survival 
rate (30%) so the compound was then administered at the lower concentrations of 2.5 μg/embryo, where 22% of 
the treated embryos survived and then at 1 μg/embryo, where the survival rate was 16%. Embryos treated with 
this drug had malformation of the blood vessels and necrosis in the YSM, and twisted spinal cords (Fig. 3E). 
Everolimus showed no impact on the survival rate at 5 μg/embryo with an 80% survival rate but at 10 μg/embryo 
survival decreased to 62.5%. Embryos treated with everolimus also had hemorrhaging, spinal cord twisting and 
necrosis in the YSM (Fig. 3F). Whilst having the highest survival rate of all treatment groups (no death occurred 
at 5 μg/embryo) vandetanib still induced defects in treated embryos, such as limb reductions, micropthalmia, 
twisted spinal cords, and necrosis and hemorrhaging in the YSM, and was shown to decrease the survival rate 
at 10 μg/embryo (74% survival). TNP-470 at 5 μg/embryo had a survival rate of 25%. At 10 μg/embryo reduced 
survival to 50% and caused twisting of the spinal cord. At the higher concentrations of 20 μg/embryo survival 
was again 50%.
Our results showed that all the drugs tested in this study are detrimental to the development of chicken 
embryos. Additionally at high concentrations every drug screened is lethal to the developing embryo, at the 
developmental time point tested. In this assay, all compounds caused defects, and all defects were comparable to 
those induced by CPS49 (Fig. 3H).
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Anti-angiogenic compounds cause limb defects when applied directly to the developing limb 
bud of chicken embryos. Given the potency of these drugs and the resulting embryonic lethality we 
focused our attention on how the drugs affect limb development. The developing limb bud is a well studied 
morphological assay22,41,42 ideal for understanding mechanisms of embryogenesis and how drugs influence this 
process. Moreover, other anti-angiogenic drugs like thalidomide and valproate cause limb defects21,42–44. Here 
we wanted to investigate if the test compounds cause limb defects and if the damage they induce are comparable 
Anti-angiogenic drug(REF)
Primary target/s of 
action
Approved 
Indications Clinical Toxicities
Defects in animal models
Defects produced 
in chicken 
embryosAnimal(REF)
Systemic 
exposure 
(AUC) 
compared 
to human 
exposure Defects produced
Sunitinib45
Inhibition of 
VEGFR1/2/3, 
PDGFRα /β 
Pancreatic 
neuroendocrine 
tumors, 
kidney cancer, 
gastrointestinal 
stromal tumor
Cardiotoxicity
Rat55 5.5× 
Embryolethality 
increased, fetal skeletal 
malformations (ribs/
vertebrae)
Embryolethality 
increased, 
limb, spinal, 
microopthalmia, 
growth inhibition, 
necrosis of YSMRabbit55 0.3× 
Increased 
embryolethality, cleft 
palate malformations
Sorafenib45
Inhibition of CRAF, 
BRAF, VEGFR1/2/3, 
PDGFRβ 
Thyroid cancer, 
liver cancer, kidney 
cancer
Cardiotoxicity
Rat56
0.008× 
Increased post 
implantation loss, 
resorptions, skeletal 
retardations, retarded 
fetal weight
Embryolethality 
increased, limb, 
growth inhibition, 
necrosis of YSM
Rabbit56
Axitinib57 VEGFR1/2/3 Renal cell carcinoma Cardiotoxicity Mouse
58 10× 
Increased post 
implantation loss, cleft 
palate malformation, 
variation in skeletal 
ossification
Embryolethality 
increased, limb, 
growth inhibition, 
necrosis of YSM
Pazopanib59 VEGFR1/2/3, PDGFR
Advanced soft tissue 
sarcoma, advanced 
renal cell carcinoma
Cardiotoxicity
Rat60 0.1× 
Teratogenic, 
embryotoxic, fetotoxic 
& abortifacient. 
Cardiovascular 
malformations, 
incomplete/absent 
ossification, reduced 
fetal body weight, pre- 
and post-implantation 
embryolethality
Embryolethality 
increased, limb, 
spine, necrosis of 
YSM
Rabbit60 0.02× 
Increased post-
implantation loss, 
abortion, 100% litter loss
Vandetanib61 VEGFR2, EGFR
Unresectable, 
locally advanced 
or metastatic 
medullary thyroid 
cancer
Cardiotoxicity Rat62 0.03×−0.4× 
Increased pre- & 
post-implantation 
loss, malformations of 
heart vessels, skeletal 
variations, delayed 
ossification of the skull, 
vertebrae & sternum.
Embryolethality 
increased, 
limb, spine, 
microopthalmia, 
necrosis of YSM
Everolimus63 Mammalian target of rapamycin (mTOR)
Subependymal giant 
cell astrocytoma, 
advanced hormone 
receptor positive/
HER2-negative 
breast cancer, 
progressive 
neuroendocrine 
tumors of 
pancreatic origin, 
advanced renal cell 
carcinoma
Stomatitis, 
noninfectious 
pneumonitis, rash, 
hyperglycemia and 
immunosuppression
Rat64 0.04× 
Increased resorption, 
pre- and post-
implantation loss, 
decreased numbers 
of live fetuses, 
malformation and 
retarded skeletal 
development
Embryolethality 
increased, 
limb, spine, 
microopthalmia, 
necrosis of YSM
Rabbit64 1.6× Increased resorptions
TNP-47065 MetAP2 Not approved Neurotoxicity Mice65 Below human Complete failure of embryonic growth
Embryolethality, 
cranial 
hemorrhaging, 
micropthalmia, 
limb defects, spine
Thalidomide22,66/CPS4942,67 Cereblon, Tubulin, sGC22/unknown
Approved- multiple 
myeloma/Not 
approved
Somnolence, 
constipation, 
neuropathy, venous 
thromboembolism 
and rash/unknown
Mouse66 
(strain 
specific) 
Rabbit/
Chicken20,22
At 
recommended 
human dose/
Not applicable
Increased resorptions, 
embryotoxicity, eye 
defects
Embryolethality, 
cranial 
hemorrhaging, 
micropthalmia, 
limb defects, spine
Table 1.  A comparison of toxicities and defects produced by each anti-angiogenic and anti-cancer drug. 
A brief summary of the main mechanism(s) of action of each drug screened and their clinical uses are given. 
Also shown are human toxicities, the defects produced when tested in pregnant animals, including rodents and 
rabbits, and defects produced in the developing chicken embryo model.
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to defects caused by other anti-angiogenic drugs. We therefore established a method where a small filter paper 
square soaked in the drug of interest could be placed directly onto the limb tissue of the embryo, thus avoiding or 
minimalizing exposure of the drug to other developing tissue/structures and retaining high viability. Filter paper 
squares were soaked for 10 minutes prior to removal of the embryonic membrane of HH St 18–20 (E2.5-E3) 
chicken embryos, then placed over the developing limb bud. Filter paper squares soaked in 0.1% DMSO had no 
effect on limb outgrowth. Tissue was necrotic-looking in TNP-470 treated embryos, and as such we were not able 
to ascertain the cartilage patterns in these embryos.
Utilizing this methodology we found that when the developing limb buds of chicken embryos are exposed 
directly to the test compounds they disrupted the patterning of the limb, leading to loss of cartilage and develop-
mental malformations (Fig. 3A’–H’,I). In cases where the filter paper sponge was placed close to the YSM, malfor-
mation of the vessels near the drug soaked sponge could be observed, similar to destruction of the YSM seen in 
global treatment, confirming the potent anti-angiogenic effects.
These in vivo chicken embryology experiments demonstrate that all of the anti-angiogenic drugs examined 
were teratogenic to the developing chicken embryo. When the limbs of chicken embryos are exposed to these 
drugs they induce limb defects, which can be reminiscent to those formed by the human teratogen thalidomide, 
as seen by loss and reduction of limb elements20,22,40,42.
Anti-angiogenic compounds target the developing vasculature of zebrafish embryos. We 
then examined the extent and nature of the anti-angiogenic effects of the compounds using transgenic fli1:EGFP 
Figure 1. Inhibition of endothelial cell proliferation. Anti-angiogenic drugs were screened in a concentration 
gradient in the HUVEC culture assay. The drugs maximal activity was within the range 1 nM–1000 nM. 
Cell proliferation was assessed using a CCK-8 assay (Dojindo). Statistical analysis by two-way Anova. Error 
represents the standard error of the mean.
Figure 2. Embryo survival following anti-angiogenic drug exposure. (A) Survival of chicken embryos at 
48 hours with global treatment over a concentration gradient versus control embryos treated with 0.1% DMSO. 
(B) The survival of fli1:EGFP zebrafish embryos at 24 hours after exposure to drug versus control embryos 
treated with 0.1% DMSO.
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zebrafish embryos. The vasculature of these fish is tagged with EGFP and the transparency of the zebrafish allows 
for visualization of the forming blood vessels and any effect of anti-cancer drugs on their development over time 
(Fig. 4). A known anti-angiogenic and teratogenic compound (CPS49) was screened alongside the drugs as a pos-
itive control at 10 μ g/mL (30 μ M), a previously established anti-angiogenic concentration20. Embryos treated with 
CPS49 had a significant reduction in both blood vessel outgrowth and the number of forming vessels (Fig. 4J) 
Figure 3. Anti-angiogenic drugs cause tissue damage in chicken embryos. Examples of teratological defects 
induced with anti-angiogenic compounds. (A) Control embryo as imaged in ovo. (A’) Control cartilage stain; 
(B) Sunitinib treated embryo and resulting (B’) cartilage pattern of the limb; (C) Sorafenib treated embryo and 
resulting (C’) cartilage pattern of the limb; (D) Axitinib treated embryo and resulting (D’) cartilage pattern 
of the limb; (E) Pazopanib treated embryo and resulting (E’) cartilage pattern of limb; (F) Everolimus treated 
embryo and resulting (F’) cartilage pattern of limb; (G) Vandetanib treated embryo and resulting (G’) cartilage 
pattern of the limb; (H) CPS49 treated embryo and resulting limb cartilage (H’) pattern. (I) Reductions in 
cartilage elements of the developing chicken forelimb after treatment with the anti-angiogenic compounds. 
Labelling: white asterisk indicates eye defect, black asterisk labels necrosis in YSM, white arrow head indicates 
hemorrhaging, black arrow head indicate limb reduction, black arrow indicates twisting of the spinal cord; 
cartilage patterns: (h) humerus, (r) radius, (u) ulna, (d1-3) digits 1, 2 and 3, and (?) represents an unknown 
cartilage element. Scale bars: A,B,D–H: 1000 μ m, C: 500 μ m, (A’–H’) 500 μ m. Error represents the standard 
error of the mean where ns = p > 0.05, * p < 0.05, * * p < 0.01, * * * p < 0.001.
www.nature.com/scientificreports/
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when compared to vehicle control (0.1% DMSO) treated embryos (Fig. 4B). The embryonic survival rate also 
decreased to 50% (Fig. 2B).
Treatment with all of the compounds blocked vasculature development, as characterized by a decrease in both 
stalk number and outgrowth (Fig. 4B–L). Like CPS49, the survival rates of treated embryos were also reduced 
compared to control embryos (Fig. 2B). When treated with sunitinib (Fig. 4D) at 10, 50 and 100 μ g/mL, survival 
decreased to 61.90%, 21.05%, and 0% respectively. With sorafenib (Fig. 4E), at 10 and 50 μ g/mL the survival dropped 
to 18.18% and 15.38%. No embryos survived treatment at 100 μ g/mL. Treatment with axitinib (Fig. 4F) decreased 
the survival to similar numbers at all concentrations tested (10 μ g/mL, 40%; 50 μ g/mL, 42.12%; 100 μ g/mL, 
38.89%). Vandetanib (Fig. 4C) treatment at 10 μ g/mL reduced survival to 60%, at 50 μ g/mL it was reduced to 
15.38% and at 100 μ g/mL it dropped again to 10%. Treatment with everolimus (Fig. 4H) did not impact the sur-
vival of the embryos at 10 μ g/mL or 50 μ g/mL however at 100 μ g/mL survival was reduced to 35.71%. Pazopanib 
(Fig. 4G) also did not affect the survival at 10 μ g/mL, but did at 50 μ g/mL (83.33%) and 100 μ g/mL (50%). At low 
doses (< 200 μ g/mL) TNP-470 (Fig. 4I) was shown to have little effect. At 200 μ g/mL the drug became highly 
toxic, killing 90% of treated zebrafish, and reducing vessel outgrowth.
These data demonstrate that these compounds affect embryonic blood vessels rapidly within 24 hours of drug 
exposure. The drugs appear to be more anti-angiogenic than CPS49 on fli1:EGFP embryos. Of the compounds 
screened sunitinib, sorafenib, axitinib and pazopanib were the most potent, reducing vessel outgrowth at similar 
Figure 4. Anti-angiogenic anti-cancer drugs target intersomitic vessel outgrowth in fli1:EGFP embryos. 
Schematic of zebrafish embryo at 48 hpf. Black rectangular box indicates the imaging area used within this 
figure. (B) Treatment with 0.1% DMSO, (C) vandetanib (100 μ g/mL), (D) sunitinib (100 μ g/mL), (E) sorafenib 
(100 μ g/mL), (F) axitinib (100 μ g/mL), (G) pazopanib (100 μ g/mL), (H) everolimus (100 μ g/mL), (I) TNP-470 
(100 μ g/mL), and (J) CPS49 (10 μ g/mL). (K) Vessel outgrowth and (L) number is reduced with anti-angiogenic 
treatment over a concentration gradient, with the exception of TNP-470 and vandetanib for vessel number. 
White arrow-heads show reduction in vessel outgrowth, white asterisks show complete loss of vessel. Scale 
bar = 100 μ m.
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concentrations (Fig. 4K). Vandetanib and everolimus were the least potent- with the exception of TNP-470, which 
had no effect until 200 μ g/mL, when it was seen to be toxic, as indicated by high lethality in zebrafish (Fig. 2B).
Discussion
Angiogenesis inhibitors are finding widespread use in the clinic; given the paucity of published preclinical stud-
ies evaluating the mechanism of their presumed teratogenic effects we screened several targeted agents in the 
developing chicken and zebrafish embryo models to assess the developmental defects. We identify differences 
in potency between them as well as show they are potentially teratogenic. Utilizing in vitro cell culture experi-
ments we confirmed the anti-proliferative activities of the compounds in endothelial cells and compared them to 
the anti-angiogenic thalidomide analog CPS49. We demonstrated in vivo in the developing fli1:EGFP zebrafish 
embryo that these drugs target the newly developing vasculature of the embryos over a range of concentrations. 
We showed that the compounds were teratogenic to the developing chicken embryo and in some cases embryo-
lethal to zebrafish embryos.
Based on our results we observe that the anti-angiogenic potential of each inhibitor may determine the extent 
of defects produced in the animal models. For example, axitinib and sunitinib were the most anti-proliferative 
in endothelial cells, and caused more endothelial cell death than vandetanib, which was not as anti-proliferative 
at the same concentrations. However, this in vitro assay was only somewhat predictive, particularly in the case of 
pazopanib, which had one of the highest IC50s in vitro but was highly anti-angiogenic in vivo, embryotoxic and 
teratogenic. Combining the in vitro data with the vessel development in the transgenic zebrafish gave a better 
indication of teratogenic potential. For example, sunitinib showed the best response in the fli1:EGFP zebrafish 
model, vastly reducing outgrowth of naïve, newly sprouting blood vessels, and consequentially caused malforma-
tions in the developing chicken embryo associated with misregulation of vasculature developing including limb, 
spinal, microphthalmia, growth inhibition, necrosis of the YSM (Table 1).
When applied globally to chicken embryos the drugs induced tissue damage to other areas of the embryo, in 
particular twisting in the spinal cord and causing developmental delay (Table 1). At high concentrations the drugs 
were embryolethal, indicating the toxicity of these drugs (Fig. 4), and may indicate the possibility of these drugs 
to cause miscarriage. We also show than when exposed directly to the developing limb bud these drugs have the 
ability to induce limb reduction damage, which share similarities to those induced by thalidomide and some 
analogs in previous chicken embryo studies20,39. For TNP-470, at all concentrations tested the treated embryos 
could not survive the treatment long enough to allow for analysis of cartilage patterns, indicating the potency and 
embryolethality of TNP-470 in this model. Mouse models examining TNP-470 during pregnancy have shown 
the compound to be anti-angiogenic, disrupting newly developing blood vessels in the placenta and embryonic 
eye34. The differences in potency of this compound may be due to species specificity, or the method of application. 
We hypothesized that the cause of death may be due to the drugs causing a fatal hemorrhage in one or more of 
the major blood vessels within the embryo, but further studies would be required to establish the specific cause.
Nonetheless, our study demonstrates that anti-angiogenic drugs induced defects in the developing chicken 
embryos. Other anti-angiogenic agents also cause similar damage to embryos, including, exposure to thalid-
omide and some thalidomide analogs21,22,32,33,40, CPS4920 as well as agents such as sodium valproate44. This 
data suggests that angiogenesis inhibitors, regardless of the molecular target, exhibit a common mechanism of 
teratogenicity- the loss of newly formed or forming blood vessels similar to thalidomide-induced teratogenesis 
with the developing limbs being particularly susceptible because of their relatively immature, highly angiogenic 
vessel network20,41,42.
While the production of defects are dependent on the drug applied and may indicate a variety of molecular 
targets or differences in action for teratogenic drugs, it has previously been shown in vitro that five of the com-
pounds tested in this study act through manipulation of VEGF receptor signaling, either at the receptor itself or 
on a downstream target45. As thalidomide and its analogs could also influence VEGF receptor signaling via mod-
ulation of COX246, this data may imply a common downstream pathway for both anti-angiogenic and teratogenic 
effects. Interestingly, everolimus does not act through the VEGF receptor, but rather as an inhibitor of mTOR, 
a downstream molecule of the VEGFR signaling pathway. Of the compounds screened everolimus was seen to 
be one of the least teratogenic, suggesting that specific targeting of downstream target molecules may be less 
detrimental to the developing vasculature than a general VEGF receptor (or multiple kinase receptor) inhibitor.
Our study highlights the effectiveness and benefits of the developing chicken and zebrafish embryos as model 
organisms for screening of developmental toxicity and embryotoxic potency of compounds during early drug 
development. The relative ease with which the embryos can be obtained and maintained, as well as the low cost 
of upkeep, and the rapid time to development allow for quick screening of a large amount of compounds. The 
uniformity of development of these species also allows for the comparison of drugs, and these models have been 
previously used to distinguish teratogenic profiles of different classes of compounds. We found that when exposed 
to the test compounds the chicken embryos were affected more severely than the zebrafish embryos. A possible 
explanation for this is the method of application. A solution of each drug was applied over the body of the chicken 
embryo, whereas the drugs were diluted in the water of the zebrafish embryos. While some drug may wash off 
from the chicken embryos, it is possible they receive more of the compound than the zebrafish due to the direct 
application of the drugs. It should also be noted that some drugs (including thalidomide) are known to have 
species-specific differences in action. Their may be species-specific effects regarding the toxicity of byproducts 
and structural analogs of the drug, for example, pomalidomide at potent anti-inflammatory doses, is not terato-
genic in chicken embryos, yet is in some mammalian species31.
The systems we use here accurately model the data from animal studies reported in the regulatory drug pack-
age inserts (Table 1). It should be noted that the concentrations tested here are not comparable to the concen-
trations tested in animals. Concentrations applied were lower (rat treatment is approximately 40 mg/kg) but the 
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defects produced by compounds in the developing chicken embryo assay correlated to those produced in rodent 
and rabbit studies (including high death rate, skeletal malformations, microphthalmia). The ability of chicken 
embryos to produce embryonic defects such as those seen when tested in higher animal species emphasizes the 
practical uses of our models for preliminary identification of potential teratogens, but thorough testing in higher 
species remains essential.
Many countries have programs to limit the chance of exposure to teratogens (for example, the S.T.E.P.S program 
utilized in the U.S. for the safe prescribing of thalidomide) but most anti-angiogenic drugs are not used with such pro-
grams. Moreover, there is an increased risk of an epidemic of children being born with defects in countries where there 
are reduced restrictions on drug availability, and where drug sharing is common practice (such as Brazil)21,22,47–49. The 
increased incidence of anti-angiogenic drug use requires safeguards in prescribing23,50. Additionally, for the majority 
of drugs approved for use in the U.S., the teratogenic risks in human pregnancy are unknown51; thus, thorough drug 
screening to identify potential teratogenic drugs and/or common mechanisms of teratogenicity is warranted.
In conclusion, we have demonstrated that different classes of anti-angiogenic drugs are teratogenic and cause 
surprisingly similar damage in chicken embryos, suggesting similar or shared mechanisms resulting in terato-
genesis. These results provide support for a concept and screening process using the developing chicken embryo 
and zebrafish embryo as validated model systems to screen novel angiogenesis inhibitors undergoing preclinical 
development in order to identify a potential teratogenic profile and to promote the safety of a diverse spectrum of 
drugs with anti-angiogenic activity in women of childbearing age.
Materials and Methods
Materials. Drugs were purchased from LC Laboratories (Woburn, MA). When required, the drugs were dis-
solved in dimethyl sulfoxide (DMSO) to 40–100 mg/mL. When applied to embryos, the drug was further dis-
solved in sterile PBS giving a maximum final concentration of 0.1% DMSO (previously shown to be non toxic20. 
The known anti-angiogenic thalidomide analog CPS49 was used as a positive control, as it has been previously 
shown to induce developmental defects in both assays and show anti-angiogenic activity in vitro20,52,53.
Endothelial Cell Proliferation Assay. HUVEC cells were purchased from ATCC (Manassas, VA) and 
cultured as previously described30. No further authentication was performed. Cells were seeded at 6.5 × 104 cells 
per well in 100 μ L of medium per well. Drugs were diluted in prewarmed DMEM. Serial dilutions were performed 
from 1000–0.1 nM. The cells were left to grow for 18 hours with exposure to vehicle control (DMSO) or drugs. 
Experiments were done in triplicate each time. Cellular proliferation was assessed using a CCK-8 assay (Dojindo, 
Rockville, MD). All plates were read at 450 nm.
Chicken embryology experiments. Fertilized white leghorn chicken embryos purchased from Henry 
Stewart Ltd. (Herefordshire, United Kingdom) were maintained in an incubator as described previously31. At 
Hamburger and Hamilton stage 18–20 (E2.5-3)54 the eggs were windowed and the embryos were prepared for 
drug exposure. To establish a dose response the drugs were applied once to the embryos and growth was moni-
tored as described previously31. In a second set of experiments, filter paper squares were cut 100 μ m × 100 μ m and 
soaked in the compound of interest for 10 minutes. While the filter paper squares absorbed the solution, embry-
onic membranes were removed and the sponge was then placed onto the limb bud. The eggs were sealed with tape 
and returned to an incubator. The embryos were checked daily for developmental defects and to ensure the filter 
paper squares remained in place. Control embryos were treated with 100 μ L PBS with 0.1% DMSO. Embryos were 
removed from the eggs and fixed in 5% TCA at 4 degrees for 24 hours. Embryos were then washed in alcian blue 
for 8 hours, and placed in acid ethanol over night before being dehydrated in 100% ethanol for three one hour 
treatments. The tissue was then cleared in methyl salicylate. Cartilage was imaged and subsequently measured 
using a graticule scale and ImageJ. A minimum of 8 embryos was used per drug, per concentration. All animal 
work was licensed and carried out in accordance with and with approval of UK Home Office and Institutional 
ethical and welfare guidelines.
Zebrafish embryology. fli1:EGFP zebrafish were obtained from the Zebrafish international Resource 
Centre29 and maintained in an approved aquarium habitat at 28 °C. At 24 hours post fertilization (hpf) the 
embryos were checked for GFP expression using a fluorescent microscope and manually dechorionated with 
forceps, exposed to either a vehicle control, or an anti-angiogenic anti-cancer compound (at 24 hpf) for 24 hours 
and imaged at 48 hpf. At this point the embryos were anaesthetized in 0.1% tricaine and the length and number of 
intersegmental vessels (ISV) were quantified as previously described31. A minimum of 10 embryos were screened 
per drug, per concentration, and experiments were performed in triplicate. All animal work was licensed and car-
ried out in accordance with and with approval of UK Home Office and Institutional ethical and welfare guidelines.
Imaging and analysis. Photography was performed used a Nikon SMZ1500 fluorescent microscope. All 
measurements were completed using Image J software and analyses conducted through Graphpad Prism. For 
statistical considerations all results were presented as mean with standard error of the mean (SEM), and p < 0.05 
as the criterion for statistical significance. Figures were prepared using Adobe Photoshop.
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